Ocrelizumab: Additional Phase II data

Additional data from an ongoing, 96-week, dose-finding Phase II trial in 220 patients with RRMS showed that 600 and 2,000 mg ocrelizumab significantly reduced the number of gadolinium-enhancing T1 lesions relative to placebo at week 24, the primary endpoint, by 89% and 96%, respectively (p<0.0001 for both). Low- and high-dose ocrelizumab also met the secondary endpoint of significantly reducing ARR relative to placebo at week 24 (80% and 73%, respectively; p=0.0005 and p=0.0014). Patients received 600 mg ocrelizumab, 2,000 mg ocrelizumab, 1 cycle of placebo followed by ocrelizumab, or 1 cycle of Avonex interferon beta-1a followed by ocrelizumab. ...